Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06707493 · ClinicalTrials.gov registry record · Phase 2
Ivosidenib as Post-HSCT Maintenance for AML
A Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT06707493 is a Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 75 participants, below the 143-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (48% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06707493, a Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ivosidenib
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2030-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06707493
The ClinicalTrials.gov registry entry for NCT06707493 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (48% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06707493 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06707493 about?
NCT06707493 is a clinical study titled "Ivosidenib as Post-HSCT Maintenance for AML". This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
What is the current status of trial NCT06707493?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-01-16. Estimated completion is 2030-01-01.
What conditions does trial NCT06707493 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML), IDH1 Mutation, Hematopoietic Stem Cell Transplant (HSCT).
What interventions are being tested in trial NCT06707493?
The interventions under investigation include: Placebo (DRUG), Ivosidenib (DRUG).
Who is sponsoring clinical trial NCT06707493?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06707493 being conducted?
This trial has 3 study locations across Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
RECRUITING · Phase 2
-
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RECRUITING · Phase 2
-
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 2
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.